ASCO 2015 | Neoadjuvant abiraterone acetate plus leuprolide acetate in localised high-risk prostate cancer
Eleni Efstathiou
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, from The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa in patients with localised high-risk prostate cancer.
Related videos
1:27
A promising future for gemcitabine-oxaliplatin in cisplatin-unfit advanced urothelial carcinoma
Jae-Lyun Lee
1:15
Changing kidney cancer treatment landscape
Ignacio Duran
5:12
Darolutamide for nmCRPC: results of the ARAMIS trial
Iris Kuss
4:21
COACH trial update: GemOx vs. GCb in cisplatin-unfit advanced urothelial carcinoma
Jae-Lyun Lee
2:45
Interaction of darolutamide with substrates of CYPs and P-gp
Christian Zurth
